{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:33:44Z","timestamp":1734068024377,"version":"3.30.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,12]]},"DOI":"10.7759\/cureus.75614","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T01:42:57Z","timestamp":1734054177000},"source":"Crossref","is-referenced-by-count":0,"title":["Pyoderma Gangrenosum With Severe Ankle Ankylosis Complicated by Rheumatoid Arthritis Successfully Treated Using Anti-tumor Necrosis Factor: A Case Report"],"prefix":"10.7759","author":[{"given":"Takaaki","family":"Nagase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Takakubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Wanezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Aso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond J","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG. Pyoderma gangrenosum: treatment options. Drugs. 2023, 83:1255-67. 10.1007\/s40265-023-01931-3","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05253-7","article-title":"Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study","volume":"40","author":"Kridin K","year":"2021","unstructured":"Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study. Clin Rheumatol. 2021, 40:521-8. 10.1007\/s10067-020-05253-7","journal-title":"Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14658","article-title":"Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey","volume":"46","author":"Yamamoto T","year":"2019","unstructured":"Yamamoto T. Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey. J Dermatol. 2019, 46:e145-6. 10.1111\/1346-8138.14658","journal-title":"J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum - a guide to diagnosis and management","volume":"19","author":"George C","year":"2019","unstructured":"George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond). 2019, 19:224-8. 10.7861\/clinmedicine.19-3-224","journal-title":"Clin Med (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxad051","article-title":"Pyoderma gangrenosum after surgery for\u00a0forefoot deformity in\u00a0a patient with rheumatoid arthritis: a case report","volume":"8","author":"Mori Y","year":"2023","unstructured":"Mori Y, Izumiyama T, Otsuka K, et al.. Pyoderma gangrenosum after surgery for\u00a0forefoot deformity in\u00a0a patient with rheumatoid arthritis: a case report. Mod Rheumatol Case Rep. 2023, 8:11-5. 10.1093\/mrcr\/rxad051","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan SM","year":"2012","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012, 132:2166-70. 10.1038\/jid.2012.130","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.001","article-title":"Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis","volume":"83","author":"Xu A","year":"2020","unstructured":"Xu A, Balgobind A, Strunk A, Garg A, Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol. 2020, 83:425-9. 10.1016\/j.jaad.2019.08.001","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100099","article-title":"Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor","volume":"4","author":"Scheinberg M","year":"2021","unstructured":"Scheinberg M, Machado LA, M Castro LG, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021, 4:100099. 10.1016\/j.jtauto.2021.100099","journal-title":"J Transl Autoimmun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxac023","article-title":"Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature","volume":"7","author":"Ohmura SI","year":"2023","unstructured":"Ohmura SI, Homma Y, Hanai S, Otsuki Y, Miyamoto T. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature. Mod Rheumatol Case Rep. 2023, 7:9-13. 10.1093\/mrcr\/rxac023","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16401","article-title":"The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Jockenh\u00f6fer F","year":"2019","unstructured":"Jockenh\u00f6fer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019, 180:615-20. 10.1111\/bjd.16401","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arg\u00fcelles-Arias F","year":"2013","unstructured":"Arg\u00fcelles-Arias F, Castro-Laria L, Lobat\u00f3n T, et al.. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013, 58:2949-54. 10.1007\/s10620-013-2762-2","journal-title":"Dig Dis Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0336-0","article-title":"Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis","volume":"20","author":"Tada M","year":"2010","unstructured":"Tada M, Nakanishi T, Hirata C, et al.. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol. 2010, 20:598-601. 10.1007\/s10165-010-0336-0","journal-title":"Mod Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases","volume":"162","author":"Marzano AV","year":"2010","unstructured":"Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, Crosti C. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010, 162:100-7. 10.1111\/j.1365-2249.2010.04201.x","journal-title":"Clin Exp Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16337","article-title":"Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study","volume":"49","author":"Yamasaki K","year":"2022","unstructured":"Yamasaki K, Yamanaka K, Zhao Y, Iwano S, Takei K, Suzuki K, Yamamoto T. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study. J Dermatol. 2022, 49:479-87. 10.1111\/1346-8138.16337","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich S","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019, 10:282. 10.3389\/fphar.2019.00282","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51490","article-title":"Pyoderma gangrenosum: the impact of treatment non-adherence on disease progression","volume":"16","author":"Iliescu C","year":"2024","unstructured":"Iliescu C, Popa L, Mihai M, Popescu MN, Beiu C. Pyoderma gangrenosum: the impact of treatment non-adherence on disease progression. Cureus. 2024, 16:e51490. 10.7759\/cureus.51490","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/316078-pyoderma-gangrenosum-with-severe-ankle-ankylosis-complicated-by-rheumatoid-arthritis-successfully-treated-using-anti-tumor-necrosis-factor-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T01:42:58Z","timestamp":1734054178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/316078-pyoderma-gangrenosum-with-severe-ankle-ankylosis-complicated-by-rheumatoid-arthritis-successfully-treated-using-anti-tumor-necrosis-factor-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.75614","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}